Treatment of Gram-negative bacterial infections by potentiation of antibiotics

Thomas P Zabawa1, Michael J Pucci1, Thomas R Parr1

  • 1Spero Therapeutics, 675 Massachusetts Avenue, Cambridge, MA 02139, United States.

Insights

New potentiator molecules are being developed to combat antibiotic-resistant Gram-negative bacterial infections. These compounds disrupt the bacterial outer membrane, enhancing antibiotic effectiveness and addressing critical treatment challenges.

Area of Science:

  • Antimicrobial resistance
  • Bacterial pathogenesis
  • Drug discovery

Background:

  • Antibiotic-resistant Gram-negative bacterial infections pose significant clinical challenges.
  • The outer membrane of Gram-negative bacteria acts as a barrier to many antibiotics.

Purpose of the Study:

  • To explore advanced potentiator molecules for combination therapy against resistant Gram-negative infections.
  • To overcome the permeability barrier of Gram-negative bacterial outer membranes.

Main Methods:

  • Evaluation of novel cationic potentiator molecules.
  • Investigating the mechanism of outer membrane disruption by potentiators.
  • Assessing potentiators for use in combination therapy.

Main Results:

  • Potentiator molecules disrupt the negatively charged outer membrane of Gram-negative bacteria.
  • This disruption allows otherwise impermeant molecules to enter bacterial cells.
  • Advanced potentiator molecules show promise in overcoming antibiotic resistance.

Conclusions:

  • Potentiator molecules offer a viable strategy to restore antibiotic susceptibility in resistant Gram-negative pathogens.
  • Development of advanced potentiators aims to mitigate toxicity issues associated with earlier compounds.
  • Combination therapy with potentiators represents a promising approach for treating challenging Gram-negative infections.

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.2K
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
15
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
10
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
37
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration01:23

Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration

Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s...
80
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
606